Novus Scientific, Inc. announced the US sales launch of TIGR™ Matrix Surgical Mesh at the Abdominal Wall Reconstruction meeting, Washington DC on June, 18. In February 2010, the US Food and Drug Administration (FDA) cleared, TIGR™ Matrix Surgical Mesh for use in reinforcement of soft tissues where weakness exists.
“The TIGR™ prosthetic adds a tool to the surgeon’s armamentarium that is currently missing – a long acting, synthetic, absorbable product that may not only be beneficial in hernia patients, but also for prophylaxis, potentially preventing the hernia from ever forming in the first place,” said David Earle MD FACS, Assistant Professor of Surgery, Tufts University School of Medicine, Springfield, MA.
TIGR™ Matrix Surgical Mesh is knitted from two different resorbable fibers that degrade at different rates following implantation. This unique patented dual-fibre design provides an initial high strength / high stability configuration, with gradually increasing compliance over time as the device is resorbed. The macroporous structure is designed to allow tissue integration for reliable tissue repair.
“TIGR™ Matrix Surgical Mesh begins a new era in patient treatment. While there is a wide range of potential applications for such a unique product, at today’s Abdominal Wall Reconstruction meeting there has been particular interest in use of TIGR™ Matrix for onlay or sublay reinforcement in conjunction with the component separation technique,” said Jim Archetto, President of Novus Scientific, Inc.
“TIGR™ Matrix Surgical Mesh fills a gap between traditional permanent mesh and biologic prosthetics. This long-term resorbable synthetic mesh defines a new product category that has never existed before, and I see many potential applications for it,” stated Karl Leblanc, MD, past president of the American Hernia Society.
With its dual stage mechanics, it provides a significant new addition to the surgeons’ toolbox. It is indicated for use for reinforcement of soft tissue where weakness exists (for example, in hernia repair). TIGR™ Matrix is warp knitted from two different resorbable fibers that degrade at different rates following implantation. The first fiber is a copolymer of glycolide, lactide and trimethylene carbonate. The second fiber is a copolymer of lactide and trimethylene carbonate. Both fibers degrade by bulk hydrolysis once implanted.
This unique patented dual-fibre design provides an initial high strength / high stability configuration, with gradually increasing compliance over time as the device loses strength and is resorbed. The macroporous structure (pore size of 1-1.5 mm at the time of implantation) is designed to allow tissue integration for reliable tissue repair.
In preclinical trials, TIGR™ Matrix has shown excellent tissue integration and early vascularization when tested under demanding conditions to cover full thickness defects of the abdominal wall in a sheep model with no defect recurrences after two years of implantation.